FDA advisers to meet in July on easing restrictions on research peptides
FDA advisers will meet in July to discuss whether to ease access restrictions on certain research peptides, a group of compounds with a dedicated following but limited safety and efficacy evidence. If restrictions are loosened, US compounding pharmacies could legally produce and dispense these drugs on prescription, effectively legalizing a thriving gray market. Critics warn that the evidence base supporting these peptides remains thin.
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!